|Articles|April 24, 2004
Genaera to begin late-stage clinical trials for squalamine
Genaera Corp., Plymouth Meeting, PA, announced late last week that itexpects to begin late-stage clinical trials by early 2005 of its experimentaldrug squalamine to treat age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
3
Rayner announces Sophi Phaco System in the US
4
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
5










































